A Phase 1/2a Clinical Trial to Evaluate the Efficacy and Safety of Allogenic Adipose Tissue-Derived Mesenchymal Stem Cell Clusters in Patients with Critical Limb Ischemia.
Park YM., Park JK., Kim HS., Yang SS., Kim JW., Kim DI.
Clinical Trial on Ankle Injury, Peripheral Artery Disease, Chronic Wound, published in Int J Stem Cells (2025) — summary generated from the PubMed abstract.
Several human studies show positive signals, while research methods and sample sizes continue to develop.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Clinical Trial
- Journal
- Int J Stem Cells (2025)
- Country
- Korea (South)
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 40091311
- PMCID
- PMC12394084
- DOI
- 10.15283/ijsc25002
Abstract (original English)
Critical limb ischemia (CLI) is a severe manifestation of peripheral arterial disease, often resulting in ischemic rest pain, non-healing ulcers, or gangrene. Due to the limited effectiveness of conventional revascularization techniques in 5%∼20% of patients, alternative therapeutic approaches are needed. This Phase 1/2a clinical trial evaluated the safety, tolerability, and efficacy of allogeneic adipose tissue-derived mesenchymal stem cell clusters (ADMSCCs) in patients with CLI who were not eligible for standard revascularization methods. The study was conducted in two phases: Phase 1 used a 3+3 dose-escalation design to determine tolerability, and Phase 2a assessed efficacy at the maximum tolerated dose. Twenty patients were treated with ADMSCCs, with safety (adverse events and dose-limiting toxicity) and efficacy (pain intensity, walking distance, and ulcer size) as primary endpoints. ADMSCCs were injected intramuscularly, and patients were monitored for 24 weeks. ADMSCCs were well-tolerated, with no serious adverse events or dose-limiting toxicities observed. Significant reductions in ischemic pain and increases in pain-free walking distance were noted at 4, 12, and 24 weeks. Although ankle-brachial index and toe-brachial index showed no significant changes, ulcer healing was observed in one participant. These findings suggest that ADMSCC therapy may be a viable alternati
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
Evidence level
Several human studies show positive signals, while research methods and sample sizes continue to develop.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Cell-Based Therapies for Post-Traumatic Ankle Osteoarthritis and Osteochondral Lesions of the Talus: A Systematic Scoping Review of an Emerging and Heterogeneous Evidence Base.
Systematic Review on Knee Osteoarthritis, Osteoarthritis, Cartilage Damage, Ankle Injury, published in Bioengineering (Basel) (2026) — summary generated from the PubMed abstract.
- 2026
Bioengineering (Basel) - Level ASystematic ReviewPubMed
Platelet-Rich Plasma Injections for Foot and Ankle Pathologies Have Significantly More Complications Compared With Hyaluronic Acid Injections, Saline Solution Injections, and Dry Needling: A Systematic Review.
Systematic Review with a reported sample of 674 on Osteoarthritis, Cartilage Damage, Tendon Injury, Ankle Injury, published in Arthroscopy (2025) — summary generated from the PubMed abstract.
- 2025
- n = 674
Arthroscopy1 citations - Level ASystematic ReviewEurope PMC
Operative management of osteochondral lesions of the talus: 2024 recommendations of the working group 'clinical tissue regeneration' of the German Society of Orthopedics and Traumatology (DGOU)
Systematic Review on Cartilage Damage, Ankle Injury, published in EFORT Open Rev (2024) — summary generated from the PubMed abstract.
- 2024
EFORT Open Rev23 citations - Level AMeta-analysisPubMed
Therapeutic Effect of Stem Cells from Different Sources on Diabetic Foot Ulcers: Systematic Review and Network Meta-Analysis.
Meta-analysis on Ankle Injury, Diabetic Foot, Chronic Wound, published in Int J Low Extrem Wounds (2024) — summary generated from the PubMed abstract.
- 2024
Int J Low Extrem Wounds - Level ASystematic ReviewEurope PMC
Visualized trends and bibliometric analysis in ankle cartilage repair from 2004 to 2024
Systematic Review on Cartilage Damage, Ankle Injury, published in Front Med (Lausanne) (2024) — summary generated from the PubMed abstract.
- 2024
Front Med (Lausanne) - Level ASystematic ReviewPubMed
Adipose-derived stem cells applied to ankle pathologies: a systematic review.
Systematic Review on Osteoarthritis, Cartilage Damage, Ankle Injury, Scar, published in Musculoskelet Surg (2023) — summary generated from the PubMed abstract.
- 2023
Musculoskelet Surg2 citations